Page 123 - Vitamin D and Cancer

110 Y. Ma et al.

43. Maeshima Y, Colorado PC, Kalluri R (2000) Two RGD-independent alpha vbeta 3 integrin
binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 275:
23745–23750
44. Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB, Hopfer
H, Xiao Y, Stillman IE, Kalluri R (2000) Distinct antitumor properties of a type IV collagen
domain derived from basement membrane. J Biol Chem 275:21340–21348
45. ÓReilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y,
Sage EH, Folkman J (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the
suppression of metastases by a Lewis lung carcinoma. Cell 79:315–328
46. ÓReilly MS, Pirie-Shepherd S, Lane WS, Folkman J (1999) Antiangiogenic activity of the
cleaved conformation of the serpin antithrombin. Science 285:1926–1928
47. Voest EE, Kenyon BM, ÓReilly MS, Truitt G, D’Amato RJ, Folkman J (1995) Inhibition of
angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581–586
48. Yue TL, Wang X, Louden CS, Gupta S, Pillarisetti K, Gu JL, Hart TK, Lysko PG, Feuerstein
GZ (1997) 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in
endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase
signaling pathway and Fas expression. Mol Pharmacol 51:951–962
49. Abe R, Shimizu T, Yamagishi S, Shibaki A, Amano S, Inagaki Y, Watanabe H, Sugawara H,
Nakamura H, Takeuchi M, Imaizumi T, Shimizu H (2004) Overexpression of pigment epi-
thelium-derived factor decreases angiogenesis and inhibits the growth of human malignant
melanoma cells in vivo. Am J Pathol 164:1225–1232
50. Doll JA, Stellmach VM, Bouck NP, Bergh AR, Lee C, Abramson LP, Cornwell ML, Pins
MR, Borensztajn J, Crawford SE (2003) Pigment epithelium-derived factor regulates the
vasculature and mass of the prostate and pancreas. Nat Med 9:774–780
51. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ (1990)
Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides.
Science 247:77–79
52. Corbacho AM, Martinez De La Escalera G, Clapp C (2002) Roles of prolactin and related
members of the prolactin/growth hormone/placental lactogen family in angiogenesis.
J Endocrinol 173:219–238
53. Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, Wei BY, Stetler-Stevenson WG
(2003) TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell
114:171–180
54. Moses MA, Wiederschain D, Wu I, Fernandez CA, Ghazizadeh V, Lane WS, Flynn E,
Sytkowski A, Tao T, Langer R (1999) Troponin I is present in human cartilage and inhibits
angiogenesis. Proc Natl Acad Sci USA 96:2645–2650
55. Pike SE, Yao L, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Teruya-
Feldstein J, Wirth P, Gupta G, Tosato G (1998) Vasostatin, a calreticulin fragment, inhibits
angiogenesis and suppresses tumor growth. J Exp Med 188:2349–2356
56. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J,
Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F
(2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal
cancer. N Engl J Med 350:2335–2342
57. Huang SM, Li J, Harari PM (2002) Molecular inhibition of angiogenesis and metastatic
potential in human squamous cell carcinomas after epidermal growth factor receptor block-
ade. Mol Cancer Ther 1:507–514
58. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel
E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S
(2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular
endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refrac-
tory solid tumors. J Clin Oncol 23:965–972
59. Marzola P, Degrassi A, Calderan L, Farace P, Nicolato E, Crescimanno C, Sandri M, Giusti
A, Pesenti E, Terron A, Sbarbati A, Osculati F (2005) Early antiangiogenic activity of